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Abstract
Purpose of Review The aim of the study is to provide an overview on the possibility of treating congenital disorders prenatally
with mesenchymal stromal cells (MSCs).
Recent Findings MSCs havemultilineage potential and a low immunogenic profile and are immunomodulatory and more easy to
expand in culture. Their ability to migrate, engraft and differentiate, or act via a paracrine effect on target tissues makes MSCs
candidates for clinical therapies. Fetal and extra-fetal MSCs offer higher therapeutic potential compared to MSCs derived from
adult sources.
Summary MSCs may be safely transplanted prenatally via ultrasound-guided injection into the umbilical cord. Due to these
characteristics, fetal MSCs are of great interest in the field of in utero stem cell transplantation for treatment of congenital disease.
Keywords Mesenchymal stromal cells . Prenatal therapy . In utero stem cell transplantation
Introduction
The field of regenerative medicine has long been interest-
ed in the restorative potential of cellular therapy.
Mesenchymal stem cells (MSCs) are amongst the most
promising and widely studied cell sources for clinical
therapy. The suggestion that there existed a subset of cells
within the bone marrow which were capable of osteogenic
differentiation was first published by Friedenstein et al.,
the early pioneer of stem cell research, as early as 1966
[1]. Forty years later, in 2006, the Mesenchymal and
Tissue Stem Cell Committee of the International Society
for Cellular Therapy proposed minimal criteria to define
human MSCs. They must demonstrate plastic adherence;
must be capable of trilineage differentiation; must express
CD105, CD73, and CD90; and must lack expression of
haematopoietic surface markers [2].
MSCs are, next to haematopoietic stem cells, numer-
ically the most investigated cell type in clinical trials; as
of 2015, there were 374 registered clinical trials in the
NIH clinical trial database using MSCs, a threefold ex-
pansion of trials over the number noted in 2011 [3, 4].
Reflecting the large amount of pre-clinical research,
‘Prochymal’ became the first clinically licensed MSC
product in 2012 when it was accepted by Health
Canada to be used in severe cases of steroid-resistant
pediatric graft versus host disease [5].
Clinical attention is now focused on the potential of
MSCs to treat congenital disease prenatally. Osteogenesis
imperfecta, otherwise known as brittle bone disease, is one
such condition which shows promise for prenatal MSC
treatment. Here, we discuss the features of MSCs which
make them particularly suitable for cellular therapy, before
describing the advantages of fetal over adult stem cell
sources. We summarise current clinical experience with
fetal MSCs of fetal liver origin in prenatal cellular therapy
for osteogenesis imperfecta and discuss future prospects
for the field.
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MSCs as a Source for Cellular Therapy
A key feature of MSCs which makes them particularly suit-
able for cellular therapy is their ability to migrate towards the
site of injury and engraft into target tissues. It has been report-
ed, for example, that following a fracture, MSCs may be in-
volved in the repair of the injured bone [6]. This intrinsic
response can be exploited to deliver donor cells directly to
the site of injury even when the cells are infused systemically.
However, they may also escape from circulation. The interac-
tion between stromal cell-derived factor 1 (SDF-1), which is
released from damaged tissues, and C-X-C chemokine recep-
tor type 4 (CXCR4), a chemokine receptor expressed by
MSCs, seems to be vital to this recruitment mechanism
[7–9]. Recognition of SDF-1 by CXCR4 causes a cascade of
cytoskeletal reorganisation within the MSCs, leading to cell
migration towards the SDF-1 gradient. Indeed, CXCR4-
negative cells are unable to home to the bone following frac-
ture, suggesting that the migration of systemically
transplanted MSCs is dependent on the presence of CXCR4
[6, 10]. Following migration, MSCs must then be able to act
upon their target site. One rationale behind stem cell therapy is
that cells may engraft and differentiate, thus repopulating the
damaged organ with healthy cells. MSCs have been shown to
home to and survive in sites of damage, but reported levels are
always under 10%, decreasing with time. Surviving cells, both
fetal and adult-derived, are capable of trilineage differentiation
into osteoblasts, chondrocytes, and adipocytes [2].
An alternative reason for the beneficial effect of MSC
transplantation is that these stem cells may additionally repair
tissue by acting in a paracrine manner. The ‘MSC secretome’
consists of a wide range of factors such as cytokines,
chemokines, and growth factors released by MSCs [11].
These factors are capable of modifying the microenvironment,
stimulating endogenous cell proliferation, and preventing ap-
optosis of resident cells [12].MSCs also release large numbers
of extracellular vesicles and membrane-derived bodies con-
taining peptides, lipids, and microRNAs that are involved in
cell-to-cell communication [13, 14, 15•]. These cell commu-
nication effects could explain the therapeutic benefits that are
seen even when levels of detectable MSC-derived cells are
very low after infusion [16–19]. If this effect relates to stem
cells or the entire cell population is today unknown [20•].
MSCs have been described as ‘medicinal signalling cells’,
which secrete immunomodulatory, anti-apoptotic, anti-in-
flammatory, proangiogenic, promitogenic, and antibacterial
factors [21]. MSCs are able to directly inhibit the proliferation
of natural killer and cytotoxic T cells [22]. Specifically, MSCs
increase regulatory Tcells, indirectly decreasing the activity of
cytotoxic T cells [23]. Thus, not only are MSCs non-immuno-
genic, they are also immunomodulatory.
Finally, unlike their haematopoietic and embryological
counterparts, MSCs are a safe cell type for transplantation,
with no significant concerns reported over 15 years of clinical
use [18, 24–28, 29••]. MSCs, mainly adult in origin, have
been tested in clinical trials for a diverse variety of disorders
ranging from diabetes to graft versus host disease. Thousands
of patients have received treatment via these trials, and few
adverse events have been reported [30••]. Most importantly,
there have been no reports of malignant transformation or
teratoma formation in vivo. The transient nature of
transplantedMSCsmay be considered a positive in this regard
[3, 31].
Advantages of Fetal Versus Adult-Derived
MSCs
When compared with fetal MSCs, adult MSCs, which are
usually derived from the adherent fraction of bone marrow,
have decreased proliferative capacity [32–34], loss of ‘fitness’
[35], and decreased anti-inflammatory capacity and homing
ability [36]. However, it cannot be assumed that the earlier
stem cells are obtained the ‘better’ they are, as embryonic stem
cells (ESCs) derived from the inner cell mass of the blastocyst
are associated with not only ethical concerns, but also those of
safety. ESCs are pluripotent and must be directed towards
their differentiation pathway to the desired cell lineage in or-
der to prevent teratoma formation. Recent attention has there-
fore focused on fetal sources of MSCs, as they do not give rise
to the pluripotency-associated issues of ESCs and yet still
offer greater utility in cellular therapy than adult-derived
MSCs [33, 34, 37, 38].
MSCs, whilst only constituting a minor fraction of the stem
cell population, are proportionally much more prevalent dur-
ing fetal life than adulthood. In the second trimester, MSCs
comprise 1:3000 blood cells and 1:400 bonemarrow cells [37,
39], whilst they make up 1:10,000 bone marrow cells in a
newborn and only 1:2 × 106 in an 80-year-old [40]. Fetal
MSCs are therefore found at higher frequency in tissues than
adult MSCs and can be readily obtained from numerous
sources of both fetal and extra-fetal tissues. These comprise
fetal liver, umbilical cord, umbilical cord blood, amnion, pla-
centa, and amniotic fluid [41–43]. Amniotic fluid MSCs can
be acquired from 15 weeks of gestation, either through am-
niocentesis, amniodrainage, or late during gestation at caesar-
ean section. Amniotic fluid contains fetal cells from the am-
nion, skin, and respiratory system that can differentiate into
MSCs or HSCs [44]. Placental stem cells can be procured
from chorionic villus sampling as early as 11 weeks of gesta-
tion or at delivery from the placenta. Placenta contains a large
variety of cells including MSCs [44]. Umbilical cord blood
stem cells can be obtained from cordocentesis during pregnan-
cy or at delivery, and the umbilical cord and amnion itself are
readily available and frequently discarded, following delivery.
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Fetal liverMSC, and all of the fetal-derivedMSC listed above,
can also be obtained at termination of pregnancy.
Not only are fetal MSCs easily obtainable in relatively high
concentrations, but they also offer practical advantages over
their adult counterparts. First-trimester fetal MSCs attain four
times as many population doublings in 50 days compared to
adult MSC: 28.4 versus 7.1, a consequence of their much
shorter doubling time (30 versus 80 h) [33, 34, 37, 45–47].
This extensive proliferative capacity is also increased by the
ability of fetal MSCs to undergo more population doublings
than adult MSCs, reaching senescence after 70 doublings ver-
sus 15 to 40 in adult cells [33, 34, 48–50]. Fetal MSCs also
have about two times higher colony-forming unit-fibroblast
capacity compared to adult MSCs [34]. Fetal MSCs hence
offer advantages with respect to the practicalities of cell cul-
ture and feasibility for clinical use. Caution needs to be exe-
cuted when evaluating these data since extensive proliferation
is not equivalent to self-renewal.
In addition to being, practically speaking, a better
source of stem cells, fetal MSCs may also be more
effective in avoiding immune recognition. Fetal MSCs
are widely held to be less immunogenic than their adult
counterparts [45, 51–53]. Fetal MSCs express lower sur-
face levels of HLA class I than adult cells [34, 45, 51].
Fetal MSCs do not express cell surface or intracellular
HLA class II, whilst untreated adult MSCs are positive
for the intracellular form. When stimulated with IFN
gamma, surface expression of HLA class II is induced
after only 1 day in adult MSCs and after 7 days in fetal
MSCs [22, 51]. It therefore appears that fetal MSCs are,
at least initially, less immunogenic than adult MSCs.
Finally, fetal MSCs may also be more suitable for clin-
ical treatment given their increased ‘fitness’ as stem cells.
It has been reported that MSCs shift their differentiation
commitment from the osteogenic to the adipogenic line-
ages with increasing cellular senescence [54], and it may
be that fresh (non-senescent) fetal MSCs have superior
osteogenic therapeutic potential to that of adult MSCs.
Guillot et al. compared the basal expression of osteogenic
genes in first-trimester liver, blood, and bone marrow
MSCs to adult bone marrow MSCs and found that fetal
MSCs had higher levels of expression of all 16 osteogenic
genes [55]. When differentiated down the osteogenic
pathway, fetal MSCs reached higher levels of osteogenic
gene upregulation than adult MSCs. Similarly, Zhang
et al. found that this translated into superior osteogenic
capacity, with higher levels of calcium deposited and
higher alkaline phosphatase activity [34]. Their superior
differentiation capacity does not only apply to the osteo-
genic lineage. In addition to differentiation down the
osteo-, chondro-, and adipogenic lineages, fetal MSCs
can also differentiate into muscle cells (myoblasts) and
oligodendrocytes [27, 34, 38, 48, 56–60].
Benefits of Prenatal Treatment
There are also many potential advantages to offering stem cell
treatment at the prenatal stage.Many congenital conditions are
now diagnosed on the mid-trimester anomaly ultrasound scan,
and increasingly, non-invasive prenatal diagnosis is becoming
available even earlier for disorders such as achondroplasia and
atophoric dysplasia [61]. However, there are few prenatal
treatments available. Psychosocially, this can be a very diffi-
cult time for parents, knowing their child has a disability, with
their only options to ‘wait and see’ how their child is at birth,
wondering if their condition is worsening whilst in utero.
Treating a child affected by a congenital disease before birth
offers an improved situation for the parents of the child, to feel
that they are ‘doing something’.
Physiologically, there are many potential advantages to in
utero treatment. Treating early, before a disease has the oppor-
tunity to have an effect on a fetus, will result in a better con-
dition at birth. Furthermore, the average weight of a 20-week
fetus, at 300 g, is over ten times smaller than that of the aver-
age newborn baby. There is therefore the opportunity for
greatly increased cell dosage given the size and weight of
the fetus compared with the neonate. Additionally, the physi-
ological conditions for systemic distribution of the MSC are
better in the fetus than in the neonate or adult because the fetal
circulatory shunts such as the foramen ovale and ductus
arteriosus reduce distribution of the MSCs to the pulmonary
circulation, avoiding their sequestration in the lungs as occurs
after birth [62, 63•, 64, 65]. As described above, fetal life is a
time of stem cell proliferation and migration to different ana-
tomic compartments; thus, the transplanted stem cells will
migrate alongside affected ones. Higher levels of engraftment
during fetal life have also been reported, especially when a
fetal-to-fetal transplantation approach is applied [66]. Finally,
the relative naiveté of the immune system results in less rejec-
tion, no need for myeloablation, and permits the development
of immune tolerance towards donor cells [67–70].
Osteogenesis Imperfecta
Osteogenesis imperfecta (OI) is a disorder of type 1 collagen
with a prevalence of 1/20,000 that is commonly diagnosed
prenatally. Clinically, affected individuals experience abnor-
mal skeletal development, osteopenia, multiple painful frac-
tures, and short stature. Ninety percent of cases are autosomal
dominant, due to mutations in COL1A1 or COL1A2, the
genes encoding the subunits of type 1 collagen. The Sillence
classification published in 1978 described four types of OI,
ranging frommild type 1 to the progressively deforming types
3 and 4 and to the perinatally lethal type 2 [71]. More recently,
up to 15 other types have been described which affect genes
controlling modification and processing of type 1 collagen,
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often recessive in inheritance [72]. Current postnatal treat-
ments are non-curative and aim to decrease deformity, relieve
pain, promote normal function, and improve quality of life.
Severe cases of OI are suspected on ultrasound due to ab-
normal fetal growth, fractures, and deformity or bowing of
limbs seen in mid-gestation. Definitive diagnosis requires mu-
tation analysis on a chorionic villus sampling, amniocentesis,
or fetal blood sample and is reached using next-generation
sequencing techniques. However, currently, no antenatal treat-
ment options are available.
A number of pre-clinical studies suggest that in mouse
models of OI, MSCs transplanted in utero or in early neonatal
life equivalent to a late pregnancy human fetus are capable of
migration to the bone, engraftment, and differentiation to os-
teoblasts, where they improve bonemechanical properties and
the clinical phenotype [44, 47, 55, 73–77].
OI is diagnosed in utero, there are no current curative treat-
ments, and mouse models provide evidence of efficacy of
treatment. Therefore, OI is a condition which is amenable to
prenatal MSC therapy. Here, we summarise the clinical expe-
rience of prenatal cellular therapy with fetal-derivedMSCs for
OI.
Clinical Experience with Fetal MSCs
in Prenatal Cellular Therapy for OI
Two case studies of prenatal transplantation of allogenic hu-
man first-trimester liver-derived MSCs in type III and type IV
OI patients have been published [28, 29]. They were per-
formed at the Karolinska Institutet in Sweden and at the
National University Hospital in Singapore. Whilst it is diffi-
cult to definitively determine the effect of prenatal fetal MSC
transplantation in these two heterogeneous cases, the results
suggest that it is safe and a potential clinical benefit, particu-
larly in comparison to an untreated Canadian patient with the
same mutations as patient A who succumbed at 5 months of
age.
Patient A
Patient A, who has severe type III OI with intrauterine frac-
tures, received an infusion of 5.0 × 106 cells/kg body weight
via the umbilical vein (total dose, 6.5 × 106 cells with a via-
bility of 90%) of first-trimester liver-derived MSCs at
31 weeks of gestational age. No signs of fetal distress were
observed during the injection. The pregnancy was uncompli-
cated after the infusion, but a spontaneous preterm rupture
occurred at 35 weeks of gestational age, and patient A was
delivered by caesarean section.
Alloreactivity against donor MSCs was not detected
pre-transplantation or at 9 months or 6 years of age,
and the patient’s immunocompetency was confirmed at
all these time points.
Evidence of osteoblastic differentiation of donor MSCs
was detected in a bone biopsy specimen taken at 9 months
of age. This biopsy also showed regularly arranged and con-
figured bone trabeculae lined by a columnar layer of normal
osteoblasts, normal amount and distribution of osteocytes and
ossification, and no apparent signs of healing or remodelling.
Patient A was started on bisphosphonate therapy from
4 months of age due to vertebral compression fractures.
Patient A’s clinical course was better than expected from
her genetic mutation for the first 2 years. She experienced only
two clinically suspected fractures (a clavicular fracture at
6 weeks and a costal fracture at 9 months), and at 15 months,
a fall from 1 m resulted in a femoral fracture that healed rap-
idly after initial stabilisation with a bandage. She grew along
her own growth velocity curve at − 5 standard deviations (SD)
for height and weight. However, from 6 to 8 years of age, the
lengthwise growth decreased and the fracture frequency in-
creased, with some prolonged fractures healing. Thus, the de-
cision was made to administer a second transplant.
Patient A was administered an intravenous infusion of
2.8 × 106 cells/kg body weight (total dose, 42 × 106 cells)
from the same fetal donor as the prenatal infusion at 8 years
and 2 months of age. No adverse events (AEs) were noted.
Despite a low level of engraftment measured at 8 years
and11 months, over the next 2 years, she experienced no
new fractures (compared to the previous two fractures per
year), linear growth increasing from the − 6.5 SD to the − 6
SD curve, and decreasing bone mineralisation. Her ability to
walk improved to 1000 m without difficulty, and she started
dance classes, increased participation in gymnastics, and
played modified indoor hockey. She subsequently received
booster doses from the same donor at 10, 12, and 13 years
of age, respectively. The absence of new fractures and im-
proved growth velocity continue.
Patient B
Patient B, who had type IV OI with intrauterine fractures,
received a prenatal infusion via the hepatic vein of ~ 30 ×
106 cells/kg body weight (total dose, 40 × 106 cells) of first-
trimester liver-derived MSCs at 31 weeks of gestational age.
No signs of fetal distress were observed through 1 h post
injection. No new fractures were noted in the following
7 weeks, and the child was delivered by elective caesarean
section at 38 weeks + 3 days of gestational age.
Alloreactivity against donor MSCs was not detected pre-
transplantation or at 7 weeks post transplantation, and the
patient’s immunocompetency was confirmed at both these
time points.
Patient B was started on bisphosphonate therapy from
1 month of age because of poor mineralisation; her
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mineralisation increased from a neonatal Z score of − 7.3 to −
0.9 at 13 months of age. No new fractures were detected in the
first year of life. The patient followed her own growth curve
just below the third percentile until 1 year of age, when the
longitudinal length plateaued. Thus, a booster dose of 10 ×
106 cells/kg (total dose, 88 × 106 cells) from the same fetal
donor was administered by intravenous infusion at 19 months
of age. No AEs were observed. Her growth subsequently con-
tinued at just below the third percentile, and she started to
walk shortly after the transplantation.
The Karolinska Institutet has treated two other children
suffering from intrauterine fractures and who were diag-
nosed with type III OI prenatally, but has not yet pub-
lished the cases. The first patient was administered
10.3 × 106 human first-trimester fetal liver-derived
MSCs/kg at gestational age of 28 weeks + 3 days in
2015, and the second patient was administered 2.3 × 106
human first-trimester fetal liver-derived MSCs/kg at
corrected age of 38 weeks + 2 days. Neither patient expe-
rienced any AEs. Neither patient experienced fractures
after birth (up to 1 year and 2 months of age for the first
patient and 1 year for the second patient).
The National University Hospital in Singapore treated
one other OI patient with a prenatal infusion of 50 ×
106 cells/kg allogenic human first-trimester fetal liver-
derived MSCs at gestational age 32 weeks + 1 day in
2014. The patient experienced no AEs and no fractures
after birth (up to 1 year of age).
We are also aware of two type III OI patients with intra-
uterine fractures treated with haploidentical adult bone
marrow-derived MSCs (one dosed at 2 × 106 cells/kg body
weight and one dosed at 3 × 106 cells/kg) at 31 weeks of
gestational age in Chile in 2005 and 2006 (personal commu-
nication). No engraftment was seen (analysed in collaboration
with the Karolinska Institutet), but the two patients had no
fractures and normal growth after birth and no AEs. Long-
term status is unknown. Two type III OI patients with intra-
uterine fractures have been treated with haploidentical adult
bone marrow-derived MSCs in Italy, but no further informa-
tion is available.
Conclusions and Future Perspectives
Fetal stem cells have shown promise in reducing fracture
rates in a mouse model [49, 50, 77, 78], and engraftment
of allogeneic cells in human fetuses with OI has also been
shown [28, 29]. As discussed above, a few patients with
OI have been treated with fetal MSCs before and/or after
birth with promising results. So far, however, the MSC
treatment for OI and other diseases has been performed
on a case-by-case basis. Carefully planned and ethically
and regulatory approved clinical trials are needed to
advance the field and to determine whether these encour-
aging initial findings indeed show that prenatal therapy in
the end will benefit the patients.
One such study is the BOOSTB4 (Boost Brittle Bones
Before Birth) study that is to be initiated shortly. BOOSTB4
is a European multicenter phase I/II study with the overall aim
to develop the advanced therapy medicinal product (ATMP)
fetal MSC. In BOOSTB4, the safety, clinical effectiveness,
acceptability, and cost-effectiveness of prenatal and postnatal
transplantation or postnatal transplantation only of fetal-
derived MSCs to treat severe but not lethal forms of OI will
be evaluated.
OI serves as a useful disease model to explore the ac-
ceptability, safety, and efficacy of prenatal transplantation
of fetal MSCs. Successful clinical demonstration of
BOOSTB4 cell therapy in OI will hopefully build knowl-
edge and experience for the design of clinical trials for the
treatment of other developmental fetal disorders that could
be amenable to prenatal MSC transplantation. These in-
clude other skeletal dysplasias, muscular dystrophies, and
inborn errors of metabolism with early central nervous
system involvement that are increasingly diagnosed in
utero.
To be noted is that ethics approval and approval from
national or regional regulatory authorities are mandatory
when performing any clinical research or trials. It is im-
portant to follow directives and regulations to develop
approved processes that comply with GMP when
manufacturing ATMP products. Any AEs, side effects,
and long-term safety risks must be assessed and mitigated,
since transplanted cells may remain for many years in
patients’ bodies. Therefore, careful monitoring and ex-
tended follow-up of patients who receive pre- and postna-
tal stem cell treatments are vital.
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